Cargando…

Targeted Therapy Recommendations for Therapy Refractory Solid Tumors—Data from the Real-World Precision Medicine Platform MONDTI

Advanced therapy-refractory solid tumors bear a dismal prognosis and constitute a major challenge in offering effective treatment strategies. In this real-world retrospective analysis of our precision medicine platform MONDTI, we describe the molecular profile of 554 patients diagnosed with 17 diffe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taghizadeh, Hossein, Unseld, Matthias, Spalt, Martina, Mader, Robert M., Müllauer, Leonhard, Fuereder, Thorsten, Raderer, Markus, Sibilia, Maria, Hoda, Mir Alireza, Aust, Stefanie, Polterauer, Stephan, Lamm, Wolfgang, Bartsch, Rupert, Preusser, Matthias, A., Kautzky-Willer, Prager, Gerald W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712019/ https://www.ncbi.nlm.nih.gov/pubmed/33114048 http://dx.doi.org/10.3390/jpm10040188

Ejemplares similares

Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI
por: Kieler, Markus, et al.
Publicado: (2019)

Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Precision Medicine for the Management of Therapy Refractory Colorectal Cancer
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology
por: Prager, Gerald W., et al.
Publicado: (2019)

Gender differences in molecular‐guided therapy recommendations for metastatic malignant mesothelioma
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real‐World Precision Cancer Medicine Platform
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors
por: Taghizadeh, Hossein, et al.
Publicado: (2022)

Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients
por: Bartl, Thomas, et al.
Publicado: (2021)

Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT
por: Unseld, Matthias, et al.
Publicado: (2018)

Applied precision medicine in metastatic pancreatic ductal adenocarcinoma
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Molecularly guided treatment of metastatic parotid gland carcinoma in adults
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field
por: Marhold, Maximilian, et al.
Publicado: (2020)

The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna
por: Kiesewetter, Barbara, et al.
Publicado: (2017)

Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
por: Aust, Stefanie, et al.
Publicado: (2020)

Applied precision cancer medicine in metastatic biliary tract cancer
por: Taghizadeh, H., et al.
Publicado: (2020)

Impact of COVID‐19 lockdown on routine oncology versus emergency care at a high volume cancer centre
por: Minichsdorfer, Christoph, et al.
Publicado: (2021)

Corrected Allele Frequency of BRCA1/2 Mutations Is an Independent Prognostic Factor for Treatment Response to PARP-Inhibitors in Ovarian Cancer Patients
por: Grech, Christina T., et al.
Publicado: (2022)

The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna
por: Kiesewetter, Barbara, et al.
Publicado: (2016)

Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC
por: Bianconi, Daniela, et al.
Publicado: (2020)

The impact of COVID‐19 on cancer care of outpatients with low socioeconomic status
por: Zeilinger, Elisabeth L., et al.
Publicado: (2022)

Applied Precision Cancer Medicine in Neuro-Oncology
por: Taghizadeh, H., et al.
Publicado: (2019)

Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data
por: Oberndorfer, Felicitas, et al.
Publicado: (2021)

First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma
por: Starzer, Angelika Martina, et al.
Publicado: (2022)

Integrins in the Spotlight of Cancer
por: Bianconi, Daniela, et al.
Publicado: (2016)

PD-L1 Expression on Tumor Cells Is Associated With a Poor Outcome in a Cohort of Caucasian Nasopharyngeal Carcinoma Patients
por: Minichsdorfer, Christoph, et al.
Publicado: (2019)

The cancer survival index—A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies
por: Gaiger, Alexander, et al.
Publicado: (2022)

Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study
por: Mair, Maximilian J., et al.
Publicado: (2022)

Interactions of EGFR/PTEN/mTOR-Pathway Activation and Estrogen Receptor Expression in Cervical Cancer
por: Bartl, Thomas, et al.
Publicado: (2023)

SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic: Conclusions for crisis response at a high-volume oncology center
por: Berger, Julia M., et al.
Publicado: (2021)

Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer
por: Kieler, Markus, et al.
Publicado: (2017)

LAG-3 expression in the inflammatory microenvironment of glioma
por: Mair, Maximilian J., et al.
Publicado: (2021)

Anti-angiogenic therapies in brain metastases
por: Berghoff, Anna S., et al.
Publicado: (2018)

Targeted Therapies for Melanoma Brain Metastases
por: Berghoff, Anna S., et al.
Publicado: (2017)

Circumnavigating the challenges of COVID-19 in oncology
por: Fuereder, Thorsten, et al.
Publicado: (2020)

Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer
por: Bekos, Christine, et al.
Publicado: (2021)

A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid
por: Kieler, Markus, et al.
Publicado: (2019)

Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron
por: Mair, Maximilian J., et al.
Publicado: (2022)

Screening for post‐traumatic stress disorders in 1017 cancer patients and correlation with anxiety, depression, and distress
por: Unseld, Matthias, et al.
Publicado: (2019)

Diagnostik und Therapie des Typ 1 Diabetes mellitus (Update 2023)
por: Lechleitner, Monika, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_59ofhu7662uafoemdj1tkg767k